Spots Global Cancer Trial Database for QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer

Official Title: A Phase II Study of Neoadjuvant QL1706 Plus Chemotherapy in Participants With High-Risk TNBC Early-Stage Breast Cancer (QUEEN-Dream)

Study ID: NCT06404736

Conditions

Early Breast Cancer

Neoadjuvant Therapy

TNBC, Triple Negative Breast Cancer

Interventions

Bispecific antibody (bsAb) targeting PD-1 and CLTA-4

Albumin-bound paclitaxel

Carboplatin

Study Description

Brief Summary: This study will look at the efficacy and safety of QL1706 plus albumin-bound paclitaxel and carboplatin in a neoadjuvant setting, in high-risk, TNBC early breast cancer.

Detailed Description: This study is a single-arm, single-center, phase II clinical study designed to observe and evaluate the efficacy and safety of QL1706 combined with Pcb regimen in the neoadjuvant treatment of early-stage high-risk TNBC breast cancer. It is planned to enroll 73 subjects. After the subjects are enrolled in the study, they will receive 6 cycles of QL1706 combined with PCb regimen. A 3-week treatment cycle is used until the treatment termination event specified in the protocol occurs. The subjects will continue to undergo postoperative efficacy and safety visits after ending of the treatment.